时珍国医国药
時珍國醫國藥
시진국의국약
LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH
2009年
11期
2879-2881
,共3页
铁甲草%肝纤维化%二甲基亚硝胺
鐵甲草%肝纖維化%二甲基亞硝胺
철갑초%간섬유화%이갑기아초알
Cassia mimosoides Linn.(Leguminosae)%Hepatic fibrosis%Dimethylnitrosamine
目的 观察铁甲草醇提取物抑制二甲基亚硝胺诱导大鼠肝纤维化形成的作用效果并探讨其作用机制.方法 采用二甲基亚硝胺诱导的大鼠肝纤维化模型,用高、中、低剂量(12.6,4.2,1.4 g/kg)的铁甲草醇提液进行干预治疗,并与秋水仙碱进行对照,检测大鼠肝功能、血清透明质酸(HA)、层粘蛋白(LN)和Ⅲ型前胶原氨基端肽(PCⅢ)、 肝组织羟脯胺酸(Hyp)含量及肝脏病理组织学改变. 结果 铁甲草高、中、低剂量组血清谷丙转氨酶(ALT)及铁甲草高剂量组血清谷草转氨酶(AST)水平与模型组比较有统计学意义(P <0.05);铁甲草各剂量组大鼠肝组织Hyp含量均明显低于模型组(P <0.05).铁甲草各剂量组大鼠血清HA 、LN、 PCⅢ含量明显低于模型组,差异有统计学意义(P<0.05).铁甲草高、中、低剂量组肝组织纤维化病变明显减轻,与模型组比较,差异有统计学意义(P <0.05). 结论 铁甲草对二甲基亚硝胺诱导的大鼠肝纤维化形成具有明显的抑制作用,其机制可能与保护肝细胞和抑制胶原纤维合成有关.
目的 觀察鐵甲草醇提取物抑製二甲基亞硝胺誘導大鼠肝纖維化形成的作用效果併探討其作用機製.方法 採用二甲基亞硝胺誘導的大鼠肝纖維化模型,用高、中、低劑量(12.6,4.2,1.4 g/kg)的鐵甲草醇提液進行榦預治療,併與鞦水仙堿進行對照,檢測大鼠肝功能、血清透明質痠(HA)、層粘蛋白(LN)和Ⅲ型前膠原氨基耑肽(PCⅢ)、 肝組織羥脯胺痠(Hyp)含量及肝髒病理組織學改變. 結果 鐵甲草高、中、低劑量組血清穀丙轉氨酶(ALT)及鐵甲草高劑量組血清穀草轉氨酶(AST)水平與模型組比較有統計學意義(P <0.05);鐵甲草各劑量組大鼠肝組織Hyp含量均明顯低于模型組(P <0.05).鐵甲草各劑量組大鼠血清HA 、LN、 PCⅢ含量明顯低于模型組,差異有統計學意義(P<0.05).鐵甲草高、中、低劑量組肝組織纖維化病變明顯減輕,與模型組比較,差異有統計學意義(P <0.05). 結論 鐵甲草對二甲基亞硝胺誘導的大鼠肝纖維化形成具有明顯的抑製作用,其機製可能與保護肝細胞和抑製膠原纖維閤成有關.
목적 관찰철갑초순제취물억제이갑기아초알유도대서간섬유화형성적작용효과병탐토기작용궤제.방법 채용이갑기아초알유도적대서간섬유화모형,용고、중、저제량(12.6,4.2,1.4 g/kg)적철갑초순제액진행간예치료,병여추수선감진행대조,검측대서간공능、혈청투명질산(HA)、층점단백(LN)화Ⅲ형전효원안기단태(PCⅢ)、 간조직간포알산(Hyp)함량급간장병리조직학개변. 결과 철갑초고、중、저제량조혈청곡병전안매(ALT)급철갑초고제량조혈청곡초전안매(AST)수평여모형조비교유통계학의의(P <0.05);철갑초각제량조대서간조직Hyp함량균명현저우모형조(P <0.05).철갑초각제량조대서혈청HA 、LN、 PCⅢ함량명현저우모형조,차이유통계학의의(P<0.05).철갑초고、중、저제량조간조직섬유화병변명현감경,여모형조비교,차이유통계학의의(P <0.05). 결론 철갑초대이갑기아초알유도적대서간섬유화형성구유명현적억제작용,기궤제가능여보호간세포화억제효원섬유합성유관.
Objective The aim of this study was to observe the inhibitive effects of the extract of Cassia mimosoides linn, on dim-ethylnitrosamine-induced hepatic fibrosis in rats and to explore the action mechanism. Methods Intervention treatment with the extract of Cassia mimosoides Linn, was explored in the rats with dimethylnitrosamine-induced hepatic fibrosis at the high, intermediate, and low doses of 12.6 g/kg,4.2 g/kg,and 1.4 g/kg respectively, compared with the group treated with colchicine. Hepatic function, levels of serum hyaluronic acid (HA) , serum laminin (LN) , serum aminoterminal propeptide of type III procolla-gen (PIIINP) , hepatic hydroxyproline (Hyp) in rats were assayed and histopathological alterations in rats were examined. Results The results indicated that, compared with those in the model group, alterations in the levels of serum alanine aminotrans-ferase (ALT) in the groups treated with extract of Cassia mimosoides at low, intermediate, and high doses, and serum aspartate aminotransferase ( AST) level in the group at the high dose were statistically significant (P<0.05 ) ; hepatic hydroxyproline ( Hyp) levels in the rats treated with extract of Cassia mimosoides at various doses were significantly lower than those in the model group (P<0.05 ). Levels of serum hyaluronic acid ( HA) , serum laminin ( LN) , and serum aminoterminal propeptide of type III procollagen (PIIINP) in the groups treated with extract of Cassia mimosoides were significantly lower than those in the model group, and the differences were statistically significant (P<0.05). Hepatic fibrosis of rats in the groups treated with extract of Cassia mimosoides at high, intermediate, and low doses alleviated significantly, and the differences compared with the pathological changes in the model group were statistically significant. Conclusion It was concluded that, intragastric administration with extract of Cassia mimosoides showed significant inhibitive effects on the dimethylnitrosamine -induced hepatic fibrosis in rats, and the inhibitive mechanisms might be related with the protective effects on hepatic cells and the inhibition on collagen fiber synthesis.
